HOME >> BIOLOGY >> NEWS
ISN's Nexus Hypertension-Kidney debate

The Infinite Gain: three decades on

Delivering the Opening Plenary Lecture, John E. Hall, Guyton Professor, Chairman of Physiology and Biophysics and Director of the Center of Excellence in Cardiovascular -Renal Research (University of Mississippi Medical Center), will present on Renal-Pressure Natriuresis - An Infinite Gain Feedback Mechanism fo Long-Term Blood Pressure Regulation"

The Nexus Plenaries to follow will aim to map the relevance of Guyton's pioneering work in both present and future contexts, spanning a wide range of timely and related topics:

Genomics: Hap Map Project (Aravinda Chakravarti, USA), Proteomics of Renal Exosomes (Mark Knepper, USA), Epidemiology: the Developmental Origins of Adult Disease (David JP Barker, UK), and Circadian control of genes, cells, and organs (Ueli Schibler, Switzerland).

Biomarkers, regultators and risk factors

In alignment with the unique Nexus format, the core program will incorporate three sessions dedicated to both the bench and the 'bedside' levels. Promoting a highly multidisciplnary approach, Hypertension and the Kidney will offer it series of three parallel sessions to deliver the cutting edge basic and clinical discovery aimed at researchers, physicians and clnicians respectively. Mirrored at both levels, the Baisc Science and Clinical Sessions will offer in-depth, rigorous updates on and around RAAS and Cardiovascular Risk, Proteinuria and Hypertension and Diuretics Revisited.

The translational sessions: the jewel in the Nexus crown

The three Translational Sessions - the key and final phase in closing the bench to bedside gap - are naturally offered to all participants. Set to signpost future directions and concrete solutions in research, patient treatment and care - the ultimate step toward addressing real day to day clinical challenges. These sessions will tackle: Guyton's Concept in 2007, Salt-Regulation Effec
'"/>

Contact: Amanda Wren
amanda.wren@isn-online.org
32-473-938-672
International Society of Nephrology
10-May-2007


Page: 1 2

Related biology news :

1. Prize winners announced at ISNs World Congress of Nephrology
2. Research ends debate over benefits of butterfly defenses
3. Lawyers and ethicists debate ashley treatment in open forum
4. Center for Science Writings debate: Redesigning Humanity, March 21
5. Scientists debate the neurobiological underpinnings of amnesia
6. Genome archaeology illuminates the genetic engineering debate
7. Math and fossils resolve a debate on dinosaur metabolism
8. Physics and biology team up to tackle protein folding debate
9. Researchers say environmental pollution is important piece of social justice debate
10. Different but equal: Settling the dosage compensation debate
11. Study continues the debate on the nature of bisexual men

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission ... hardware projects are designed, built and brought to market. , The Design Lab ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... Windsor, Connecticut (PRWEB) , ... June 23, 2016 ... ... will introduce a new line of intelligent tools designed, tuned and optimized exclusively ... place September 12–17 in Chicago. The result of a collaboration among several companies ...
Breaking Biology Technology:
Cached News: